trending Market Intelligence /marketintelligence/en/news-insights/trending/ft1ns3vu7miiv9vrlxy0ea2 content esgSubNav
In This List

Adaptimmune chief technology officer to resign

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Adaptimmune chief technology officer to resign

Adaptimmune Therapeutics plc said Gwen Binder would step down as the company's chief technology officer at the end of January 2019.

Binder was the first U.S. employee of Adaptimmune in 2011, coming from the company's T-cell translational development collaboration program with the University of Pennsylvania.

Abingdon, U.K.-based Adaptimmune operates as a clinical-stage biopharmaceutical company that offers novel cancer immunotherapy products.